JDRF update on insulin supplies in the event of a no deal Brexit – January 17, 2019
Posted on 17 January 2019
JDRF is committed to ensuring that the needs of people with type 1 diabetes are taken into account and prioritised in the event of a no deal Brexit and is working closely with the Department of Health and Social Care on the situation for insulin supplies.
The UK government advises that patients, GPs, hospitals and pharmacies should not stockpile. Instead it has requested that drug manufacturers have a minimum of six weeks’ supply of stockpiled insulin, over and above their usual operational buffer stocks.
Insulin manufacturers, Novo Nordisk and Sanofi previously stated they were increasing their stockpiles to 16 and 14 weeks respectively, while Lilly is holding several months’ supply.
Now, Novo Nordisk has announced it will be increasing supplies to 18 weeks and joining other companies in testing different shipping routes in the event of delays at the UK’s main port, Dover.
Sanofi is also looking to test two alternative routes into the country, one into the east coast from the Netherlands and another route into the south coast from France.
JDRF will continue to make the Department of Health and Social Care aware of our supporters’ concerns around insulin supplies and other type 1 consumables, in the event of a no deal and will provide further updates as soon as there are any.
Want more news like this?
Sign up to our e-newsletter and get articles like this directly into your inboxSign up here